Is Wegovy Good for Weight Loss? What the Clinical Evidence Shows

Step 1: Understanding what Wegovy actually is

Wegovy is the brand name for semaglutide 2.4mg, made by Novo Nordisk. It is a GLP-1 receptor agonist, meaning it activates the same receptor as a hormone your gut releases naturally after eating. The effect is threefold: appetite falls, the sensation of fullness arrives sooner, and food moves more slowly through the stomach. Together, these changes make eating less feel natural rather than effortful for most people on treatment.

It is given as a once-weekly injection just under the skin, typically in the abdomen, thigh or upper arm. Treatment starts at a low dose and increases in stages set by your prescriber, allowing your digestive system time to settle before reaching the dose where the meaningful clinical work happens. The semaglutide treatment overview covers the mechanism in more depth if you want the science.

A newer, higher 7.2mg dose now exists. The MHRA approved the dedicated single-dose 7.2mg pen on 14 April 2026, and trials at that level reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide. Whether a specific dose or pen format is available to you is something confirmed at the point of consultation.

Step 2: Reading the evidence honestly

The honest answer to "how good is Wegovy" starts with the trial data, and our page on whether Wegovy is any good works through that question in detail before we get to the numbers here. The STEP 1 trial, published in the New England Journal of Medicine, randomised adults with obesity and no diabetes over 68 weeks. Those on semaglutide 2.4mg lost an average of around 15% of body weight, compared with roughly 2.4% on placebo. That is a clinically significant difference, not a rounding error.

Results vary between individuals. Some people lose more, some less. A prescriber will discuss what realistic progress looks like for you specifically, and NICE's appraisal of Wegovy (TA875) notes that treatment should be reviewed if less than 5% weight loss is achieved after six months at the maintenance dose. That built-in checkpoint exists precisely because the medicine is not universally effective at the same level for every person who takes it.

For a broader look at how semaglutide compares across different evidence, the evidence on semaglutide for weight loss page goes into further detail. If you are asking more specifically whether semaglutide is a good weight loss drug overall, that page weighs the clinical picture against real-world expectations. It is also worth reading how Wegovy performs specifically for weight loss if your main question is about the scale of the effect.

Step 3: Who Wegovy is designed for, and who it is not

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or from 27 upwards if at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, dyslipidaemia or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. None of those figures alone guarantee a prescription; a prescriber reviews the full picture, including other medicines you take, your medical history and any contraindications.

It is not licensed for under-18s. It is not recommended during pregnancy, breastfeeding or when trying to conceive. People with a history of medullary thyroid carcinoma or MEN2 are among those for whom it is contraindicated, and anyone with a relevant history of pancreatitis or certain gastrointestinal conditions will need careful prescriber discussion.

The weighing up Wegovy's benefits and risks page addresses the trade-offs in more depth, and the weight-loss treatment overview covers how Wegovy sits alongside other licensed options.

Step 4: Side effects and what to watch for

The most common side effects are gastrointestinal: nausea, diarrhoea, constipation, indigestion and burping appear most often in the first weeks of treatment or after a dose increase, and typically settle as the body adjusts. Fatigue, headache and dizziness are also reported. The NHS medicines page on semaglutide lists the full side-effect profile and what to do about specific symptoms.

Acute pancreatitis is a known but infrequent side effect, get urgent medical help for severe, persistent stomach pain that radiates to the back, with or without vomiting. That signal applies across GLP-1 medicines and was the subject of an MHRA Drug Safety Update in January 2026. Gallbladder problems and signs of dehydration from prolonged vomiting or diarrhoea also warrant prompt contact with a healthcare professional. Any suspected side effect can be reported to the MHRA at the Yellow Card scheme.

Most people find the early GI effects manageable, particularly if they have been counselled on what to expect. One practical thing our prescribers hear often: the adjustment period feels harder than people expected but shorter too.

If you are weighing whether Wegovy is the right fit, starting with a consultation is the most useful next step. There is no obligation and no charge for the assessment itself. Check your eligibility with our prescribers and get a clear answer from someone who can actually review your details.